Intensity Therapeutics, Inc. („Intensity“ or „the Company“) (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces that the Company executed a collaboration agreement with The Swiss Group for Clinical Cancer Research SAKK („SAKK“) to conduct a Phase 2 randomized, (one to one), controlled trial evaluating clinical and biological effects of intratumoral INT230-6 followed by the standard of care („SOC“) immuno/chemotherapy vs. SOC immune/chemotherapy alone in early-stage triple-negative breast cancer („TNBC“) in 54 patients in Switzerland and selected countries in Europe (the „INVINCIBLE-4 Study“). The INVINCIBLE-4 Study is an open-label randomized two-cohort phase 2 clinical trial.
https://www.sakk.ch/en
